Risk factor
Negligible price volatility
Profitability factor
Strong margins and returns
About
Fisher & Paykel Healthcare Corporation Limited, operating with its various subsidiaries, is a global innovator in medical device technology. The company specializes in the design, production, and worldwide distribution of sophisticated products and systems. These solutions primarily cater to acute and chronic respiratory care, support during surgical procedures, and the treatment of obstructive sleep apnea (OSA) in both clinical settings and home environments. Their product lineup includes notable items such as the Airvo 2, a humidified nasal high flow system; Optiflow, designed for nasal high flow therapy; and the F&P 850 System, which offers both non-invasive and invasive ventilation capabilities. For infant care, the company supplies respiratory products used in resuscitation, continuous positive airway pressure (CPAP) therapy, and nasal high flow therapy. Hospital-grade offerings comprise humidification devices, breathing circuits, chambers, diverse masks, nasal cannulas, surgical accessories, and various interfaces. For homecare users, Fisher & Paykel provides masks, CPAP devices, data management software, humidifiers, and complementary accessories. Established in 1934, the company maintains its headquarters in Auckland, New Zealand.
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks. In particular, the stock is overpriced on P/E, 'expensive
Target Price
The average target price of FPH.AX is 35.8 and suggests 9.55% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation to